Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

被引：0
作者：
Jiwon Oh
Paul W. O’Connor
机构：
[1] Johns Hopkins University,Department of Neurology
[2] University of Toronto,St. Michael’s Hospital, Division of Neurology, Department of Medicine
来源：
CNS Drugs | 2013年 / 27卷
关键词：
Multiple Sclerosis; Multiple Sclerosis Patient; Progressive Multifocal Leukoencephalopathy; Natalizumab; Glatiramer Acetate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral disease-modifying agents (DMAs) has significantly changed the landscape of therapeutic options for MS patients. Many of these oral DMAs have demonstrated satisfactory safety and tolerability profiles in clinical trial settings, but the long-term safety of these agents is an important concern. This review discusses salient points on the safety and clinical efficacy of the approved and emerging novel oral therapies in RRMS, including fingolimod, teriflunomide, dimethyl fumarate, laquinimod, and cladribine.
引用
收藏
页码：591 / 609
页数：18
相关论文
共 294 条
[1]  
Brinkmann V(2007)Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology Pharmacol Ther 115 84-105
[2]  
Matloubian M(2004)Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 427 355-360
[3]  
Lo CG(2002)Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists Science 296 346-349
[4]  
Cinamon G(2008)FTY720 modulates human oligodendrocyte progenitor process extension and survival Ann Neurol 63 61-71
[5]  
Lesneski MJ(2010)A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 387-401
[6]  
Xu Y(2010)Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 402-415
[7]  
Brinkmann V(2012)Severe relapses under fingolimod treatment prescribed after natalizumab Neurology 79 2004-2005
[8]  
Mandala S(2012)Tumefactive multiple sclerosis lesions under fingolimod treatment Neurology 79 2000-2003
[9]  
Hajdu R(2012)Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod Neurology 79 2006-2007
[10]  
Bergstrom J(2012)Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod Neurology 79 2002-2004
12345678910